BLTE BELITE BIO, INC Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1889109 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-114.7%
TTM EPS YoY-95.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-16.9%
ROA-16.6%
ROIC (approx.)-25.0%
Asset turnover—
Leverage & solvency
Liabilities / assets1.3%
Debt / equity0.00x
Current ratio50.02x
Interest coverage-42,104.00x
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio-8.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $45.38M | $29.94M | $24.84M | $8.87M | $7.42M |
| SG&A expense | $38.83M | $10.06M | $6.82M | $3.95M | $2.38M |
| Operating income | -$84.21M | -$40.00M | -$31.67M | -$12.82M | -$9.80M |
| Interest expense | $2,000 | $20,000 | $25,000 | $16,000 | — |
| Pretax income | -$77.61M | -$36.14M | -$31.62M | -$12.65M | -$9.67M |
| Income tax | $0 | $6,000 | $9,000 | — | — |
| Net income | -$77.61M | -$36.14M | -$31.63M | -$12.65M | -$9.67M |
| EBITDA | -$84.04M | -$39.83M | -$31.53M | -$12.76M | -$9.77M |
| EPS (basic) | -2.31 | -1.18 | -1.19 | -0.63 | -1.01 |
| EPS (diluted) | -2.31 | -1.18 | -1.19 | -0.63 | -1.01 |
| Weighted avg. shares (diluted) | 33.54M | 30.54M | 26.59M | 19.98M | 9.57M |
| Balance sheet | |||||
| Cash & equivalents | $352.93M | $31.68M | $88.16M | $42.09M | $17.34M |
| Short-term investments | — | $4.55M | — | — | — |
| Current assets | $494.27M | $147.07M | $89.94M | $42.81M | $17.43M |
| PP&E, net | $344,000 | $444,000 | $490,000 | $541,000 | $94,000 |
| Intangibles | $19,000 | $31,000 | — | — | — |
| Total assets | $780.56M | $152.13M | $94.64M | $44.27M | $18.35M |
| Current liabilities | $9.88M | $6.05M | $3.63M | $2.10M | $1.64M |
| Total liabilities | $10.07M | $6.31M | $4.21M | $2.77M | $1.64M |
| Shareholders' equity | $770.49M | $145.82M | $90.43M | $41.50M | -$15.09M |
| Shares outstanding | 39.34M | 31.83M | 29.15M | 24.90M | 10.27M |
| Cash flow statement | |||||
| Operating cash flow | -$36.99M | -$29.23M | -$29.84M | -$11.46M | -$7.47M |
| Capital expenditure | $71,000 | $116,000 | $63,000 | $394,000 | $74,000 |
| Free cash flow | -$37.06M | -$29.35M | -$29.90M | -$11.85M | -$7.55M |
| Investing cash flow | -$305.11M | -$110.57M | -$63,000 | -$394,000 | -$56,000 |
| Financing cash flow | $663.23M | $83.59M | $75.96M | $36.96M | -$583,000 |
| Depreciation & amortization | $172,000 | $164,000 | $139,000 | $64,000 | $30,000 |
| Stock-based compensation | $38.92M | $8.99M | $3.82M | $1.48M | $1.53M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.